

Press release from LIF – the research-based pharmaceutical industry in Sweden

## State premiums can secure new antibiotics

Stockholm/Visby, July 6 2016

**The Swedish government has decided to investigate whether a model with state premiums for new antibiotic medicines may be worth testing in actual practice.**

**The proposed model is designed to create incentives both to market new antibiotics in Sweden, and to overcome the problem that too few new antibiotics are being developed because it is not economically viable. New antibiotics should only be used for a very small number of patients, in order to fight the growing problem with AMR.**

The government decision is based upon a proposal for a new value based pricing model developed by LIF in conjunction with member companies AstraZeneca, MSD, GlaxoSmithKline and Astellas – companies that all are active in the antibiotic field.

In the new antibiotic model it is suggested that the value of “adding a new tool in the toolbox” should be measured, as compared with the traditional health technology assessment where the value of “replacing an existing tool in the toolbox” is the basis for pricing of a new pharmaceutical.

- The really exciting news is that we in Sweden can be the first to, in practice, try to find a solution to this paradox. If this works we think that it will inspire other countries, says Karolina Antonov, chief analyst at LIF, and one of the team that has developed the proposal.

- If this works, it might inspire other countries and the model will be more widespread. It is also possible that this model may create incentives to market certain older pharmaceuticals that presently are not available on the Swedish market because marketing them is not worthwhile for companies.

Contact:

Karolina Antonov

Chief analyst, LIF

Tel: +46 70 598 23 86